These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 24347760)

  • 1. Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease.
    Grover ND; Limaye RP; Gokhale DV; Patil TR
    Indian J Pharmacol; 2013; 45(6):547-55. PubMed ID: 24347760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zonisamide in Parkinson's disease: a current update.
    Goel A; Sugumaran R; Narayan SK
    Neurol Sci; 2021 Oct; 42(10):4123-4129. PubMed ID: 34448999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease.
    Murata M
    Curr Pharm Des; 2004; 10(6):687-93. PubMed ID: 14965331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis.
    Matsunaga S; Kishi T; Iwata N
    J Alzheimers Dis; 2017; 56(4):1229-1239. PubMed ID: 28157097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zonisamide: a new drug for Parkinson's disease.
    Murata M
    Drugs Today (Barc); 2010 Apr; 46(4):251-8. PubMed ID: 20502722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Aboulatta L; Haidar L; Abou-Setta A; Askin N; Rabbani R; Lavu A; Peymani P; Zarychanski R; Eltonsy S
    CNS Drugs; 2023 Nov; 37(11):941-956. PubMed ID: 37973769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials.
    Yan R; Cai H; Cui Y; Su D; Cai G; Lin F; Feng T
    Eur J Neurol; 2023 Apr; 30(4):1118-1134. PubMed ID: 36437702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of Parkinson's disease--up to date].
    Murata M
    Rinsho Shinkeigaku; 2008 Nov; 48(11):986-8. PubMed ID: 19198140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoamine oxidase B inhibitors for early Parkinson's disease.
    Macleod AD; Counsell CE; Ives N; Stowe R
    Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD004898. PubMed ID: 16034956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zonisamide: in Parkinson's disease.
    Yang LP; Perry CM
    CNS Drugs; 2009 Aug; 23(8):703-11. PubMed ID: 19594199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zonisamide has beneficial effects on Parkinson's disease patients.
    Murata M; Horiuchi E; Kanazawa I
    Neurosci Res; 2001 Dec; 41(4):397-9. PubMed ID: 11755227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zonisamide for the Treatment of Parkinson Disease: A Current Update.
    Li C; Xue L; Liu Y; Yang Z; Chi S; Xie A
    Front Neurosci; 2020; 14():574652. PubMed ID: 33408605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of zonisamide with non-levodopa, anti-Parkinson's disease drugs in the incidence of Parkinson's disease-relevant symptoms.
    Iwaki H; Tagawa M; Iwasaki K; Kawakami K; Nomoto M
    J Neurol Sci; 2019 Jul; 402():145-152. PubMed ID: 31151065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials.
    Tsuboi Y; Nakamura M; Maruyama H; Matsumoto Y
    J Neurol Sci; 2021 Nov; 430():120026. PubMed ID: 34715471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-dopaminergic treatments for motor control in Parkinson's disease.
    Fox SH
    Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
    Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
    Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The factors associated with impulse control behaviors in Parkinson's disease: A 2-year longitudinal retrospective cohort study.
    Kon T; Ueno T; Haga R; Tomiyama M
    Brain Behav; 2018 Aug; 8(8):e01036. PubMed ID: 29956879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zonisamide in managing impulse control disorders in Parkinson's disease.
    Bermejo PE; Ruiz-Huete C; Anciones B
    J Neurol; 2010 Oct; 257(10):1682-5. PubMed ID: 20509031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease.
    Ueno SI; Saiki S; Fujimaki M; Takeshige-Amano H; Hatano T; Oyama G; Ishikawa KI; Yamaguchi A; Nojiri S; Akamatsu W; Hattori N
    Cells; 2018 Dec; 8(1):. PubMed ID: 30597973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.